Mitoxantrone and cisplatin in recurrent and/or metastatic salivary gland malignancies.

Abstract:

:A phase II study was performed to assess the safety and efficacy of mitoxantrone and cisplatin in locally recurrent and/or metastatic carcinomas of the salivary glands. Between May 1997 and March 2001, a total of 14 patients were entered on this trial. All of them had previously undergone radical resection and 10 were subsequently treated with adjuvant radiation therapy with (n=3) or without (n=7) concomitant chemotherapy. Therapy according to the study protocol consisted of mitoxantrone given as i.v. bolus on day 1 at a dose of 12 mg/m2 and cisplatin given as 90-min infusion at a dose of 30 mg/m2 on days 1-3. We observed two partial responses (14.3%) and stabilization of disease in nine patients (64.3%); progression during therapy was noted in only three cases (21.4%). The median time to progression was 15 months (range 2-36) and the median survival time was 27 months (range 4-54). Myelosuppression was commonly observed. Leukocytopenia occurred in all patients, and was grade 3 or 4 in three (21%) and four (29%) patients. WHO grade 3 thrombocytopenia and anemia was seen in three (21%) and four (29%) patients, respectively. Non-hematologic toxicity was in general mild to moderate except for two cases (14%) of grade 3 nausea and vomiting; overall incidence rates were nausea and vomiting (n=14), stomatitis (n=6), diarrhea (n=3), alopecia (n=11), infection (n=7), increase of serum creatinine (n=3), and peripheral neuropathy (n=3). The combination of mitoxantrone and cisplatin seems to be an active and fairly well-tolerated regimen for the treatment of advanced salivary gland cancers. According to the observed high rate of abrogating progressive disease for a long duration, and the resulting promising progression-free and overall survival time, further investigation seems warranted.

journal_name

Anticancer Drugs

journal_title

Anti-cancer drugs

authors

Gedlicka C,Schüll B,Formanek M,Kornfehl J,Burian M,Knerer B,Selzer E,Scheithauer W,Kornek GV

doi

10.1097/00001813-200206000-00007

subject

Has Abstract

pub_date

2002-06-01 00:00:00

pages

491-5

issue

5

eissn

0959-4973

issn

1473-5741

journal_volume

13

pub_type

临床试验,杂志文章
  • Antitumor activity of a novel antiestrogen (Analog II) on human breast cancer cells.

    abstract::Analog II (1,1-dichloro-cis-2,3-diarylcyclopropane), previously shown to be a pure antiestrogen in mice, was examined for potential antitumor activity on human breast cancer cells in culture. In this study, Analog II produced a dose-related antiproliferative effect on the growth of estrogen receptor (ER)-positive MCF-...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199711000-00008

    authors: Jain PT,Rajah TT,Pento JT

    更新日期:1997-11-01 00:00:00

  • Interactions between taxol and camptothecin.

    abstract::Taxol is an antitumor drug which, as its mechanism of action, promotes microtubule assembly in vitro. Camptothecin (CPT) is an anticancer agent with the peculiar mechanism of poisoning eukaryotic DNA topoisomerase I. Both drugs are in clinical trials and their chemotherapeutic efficacy seems promising in refractory hu...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199607000-00007

    authors: Debernardis D,Cimoli G,Parodi S,Russo P

    更新日期:1996-07-01 00:00:00

  • Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel.

    abstract::Docetaxel is a new antimicrotubule agent that induces a predominantly sensory neuropathy that is mild in most patients. This prospective study was performed to determine if corticosteroid co-medication reduces the incidence and severity of docetaxel-induced neuropathy. Two groups of patients treated with docetaxel in ...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1097/00001813-199810000-00003

    authors: Pronk LC,Hilkens PH,van den Bent MJ,van Putten WL,Stoter G,Verweij J

    更新日期:1998-10-01 00:00:00

  • Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands.

    abstract::There is limited evidence on the costs associated with ipilimumab. We investigated healthcare costs of all Dutch patients with advanced cutaneous melanoma who were treated with ipilimumab. Data were retrieved from the nation-wide Dutch Melanoma Treatment Registry. Costs were determined by applying unit costs to indivi...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000628

    authors: Franken MG,Leeneman B,Jochems A,Schouwenburg MG,Aarts MJB,van Akkooi ACJ,van den Berkmortel FWPJ,van den Eertwegh AJM,de Groot JWB,van der Hoeven KJM,Hospers GAP,Kapiteijn E,Koornstra R,Kruit WHJ,Louwman MWJ,Piersma D,van

    更新日期:2018-07-01 00:00:00

  • Apoptosis induced by desmethyl-lasiodiplodin is associated with upregulation of apoptotic genes and downregulation of monocyte chemotactic protein-3.

    abstract::There is growing interest in the discovery of bioactive metabolites from endophytes as an alternative source of therapeutics. Identification of their therapeutic targets is essential in understanding the underlying mechanisms and enhancing the resultant therapeutic effects. As such, bioactive compounds produced by end...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e3283635a47

    authors: Hazalin NA,Lim SM,Cole AL,Majeed AB,Ramasamy K

    更新日期:2013-09-01 00:00:00

  • Imatinib mesylate (STI571; Glivec)--a new approach in the treatment of biliary tract cancer?

    abstract::Non-resectable biliary tract cancer is associated with poor prognosis due to widespread resistance to chemotherapeutic agents and radiotherapy. It is therefore essential to explore new therapeutic approaches like the inhibition of tyrosine kinases. The aim of this study was to determine the expression of c-kit and pla...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-200310000-00011

    authors: Wiedmann M,Kreth F,Feisthammel J,Deininger M,Mössner J,Caca K

    更新日期:2003-10-01 00:00:00

  • Efficient induction of apoptosis by ONYX-015 adenovirus in human colon cancer cell lines regardless of p53 status.

    abstract::The ONYX-015 virus is a mutated adenovirus that in theory selectively replicates and induces cytolysis in tumor cells lacking functional p53. The present study investigated whether ONYX-015 viral infection alone or in combination with conventional chemotherapeutic agents could significantly increase apoptosis in human...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:

    authors: Petit T,Davidson KK,Cerna C,Lawrence RA,Von Hoff DD,Heise C,Kirn D,Izbicka E

    更新日期:2002-01-01 00:00:00

  • Baicalin induces apoptosis in SW480 cells through downregulation of the SP1 transcription factor.

    abstract::Colorectal cancer occurs throughout the world but is most common in developed countries. Cancer progression is believed to be driven by genetic mutations in this complex condition. Risk factors for developing colorectal cancer include a genetic family history, long-term ulcerative colitis, and colonic polyps. The use ...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000708

    authors: Ma W,Liu X,Du W

    更新日期:2019-02-01 00:00:00

  • Endometrial stromal sarcoma of the uterus.

    abstract::Uterine sarcomas are rare tumors constituting 1-3% of all uterine malignancies. These tumors are characterized by aggressive growth and by poor overall prognosis. There is much controversy concerning diagnostic criteria and the great variation in histology, as well as the role of radiotherapy and chemotherapy in the m...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199102000-00004

    authors: Meden H,Meyer-Rath D,Schauer A,Kuhn W

    更新日期:1991-02-01 00:00:00

  • The antitumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces NF-kappaB activity in drug-sensitive MCF-7 cells.

    abstract::2-(4-Amino-3-methylphenyl)-5-fluoro-benzothiazole (5F 203) potently inhibits MCF-7 breast cancer cell growth in part by activating the aryl hydrocarbon receptor (AhR) signaling pathway. Ligands for the AhR (i.e. dioxin) have also been shown to modulate the NF-kappaB signaling cascade, affecting physiological processes...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-200502000-00004

    authors: Brantley E,Patel V,Stinson SF,Trapani V,Hose CD,Ciolino HP,Yeh GC,Gutkind JS,Sausville EA,Loaiza-Pérez AI

    更新日期:2005-02-01 00:00:00

  • Induction chemotherapy in head and neck cancer: a new paradigm.

    abstract::Five hundred and fifty thousand new head and neck cancer cases are diagnosed each year worldwide. They are mostly locally advanced squamous cell carcinoma with a poor prognosis in terms of locoregional and distant failure. A major challenge for patients with locally advanced squamous cell carcinoma is to achieve a hig...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/CAD.0b013e3283425871

    authors: Pointreau Y,Atean I,Fayette J,Calais G,Lefebvre JL

    更新日期:2011-08-01 00:00:00

  • Ifosfamide in pediatric oncology.

    abstract::Since the number of patients seen in a pediatric oncology center is relatively small, it is difficult to perform single drug phase two studies, even on a national base. This also probably explains the lack of information on ifosfamide, despite the fact that it has now been used for more than 10 years in pediatrics. As...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/00001813-199108000-00002

    authors: de Kraker J

    更新日期:1991-08-01 00:00:00

  • RNA interference targeting the R2 subunit of ribonucleotide reductase inhibits growth of tumor cells in vitro and in vivo.

    abstract::RNA interference, a posttranscriptional gene-silencing mechanism, has received considerable attention for its potential as a new therapeutic strategy to treat human diseases and conditions including cancer. Various studies have supported a role for the R2 subunit of ribonucleotide reductase in cancer progression and m...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e328013c04f

    authors: Avolio TM,Lee Y,Feng N,Xiong K,Jin H,Wang M,Vassilakos A,Wright J,Young A

    更新日期:2007-04-01 00:00:00

  • Repeat dose study of the novel proapoptotic chemotherapeutic agent alpha-tocopheryloxy acetic acid in mice.

    abstract::Alpha-tocopheryloxy acetic acid (α-TEA) is an ether derivative of vitamin E and has been shown to suppress tumor growth in various murine and human xenograft tumor models, including melanoma, breast, lung, prostate, and ovarian cancers. The purpose of this study was to assess its safety and pharmacokinetics after repe...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e32834f6271

    authors: Hahn T,Akporiaye ET

    更新日期:2012-04-01 00:00:00

  • New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004.

    abstract::An international meeting on 'New Drugs in Cancer Therapy' was held at the National Tumor Institute of Naples, on 17-18 June 2004. The first session of the meeting focused on analogs of conventional anti-cancer drugs, such as taxanes, platinum compounds, anthracyclines and topoisomerase I inhibitors. The data of a phas...

    journal_title:Anti-cancer drugs

    pub_type:

    doi:10.1097/00001813-200502000-00014

    authors: Caponigro F,Basile M,de Rosa V,Normanno N

    更新日期:2005-02-01 00:00:00

  • Amifostine administration during radiotherapy for cancer patients with genetic, autoimmune, metabolic and other diseases.

    abstract::Amifostine is a broad-spectrum cytoprotective agent approved for protection against cisplatin toxicities and radiation-induced xerostomia; strong clinical evidence exists that amifostine protects normal mucosa and lung from radiation damage. Hypotension, nausea/vomiting, fatigue and fever/rash are the main side-effect...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/00001813-200602000-00003

    authors: Koukourakis MI,Maltezos E

    更新日期:2006-02-01 00:00:00

  • Therapeutic effects of the angiogenesis inhibitor TNP-470 against carcinomatous peritonitis in mice.

    abstract::The therapeutic effects of the new anti-angiogenesis factor TNP-470 were examined against carcinomatous peritonitis in mice. In the first experiment using carcinomatous peritonitis caused by i.p. inoculation of 10(6) M5076 tumor cells, TNP-470 solution was injected i.p. in a bolus of 50 mg/kg body weight into two grou...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199506000-00012

    authors: Tsujimoto H,Hagiwara A,Osaki K,Ohyama T,Sakakibara T,Sakuyama A,Ohgaki M,Imanishi T,Watanabe N,Yamazaki J

    更新日期:1995-06-01 00:00:00

  • Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II and pharmacokinetic study in Japan.

    abstract::Tolerability and response rate to weekly combination chemotherapy with trastuzumab and vinorelbine in Japanese women with HER2-overexpressing breast cancer not previously receiving either therapy were assessed. Tumor response was evaluated every 4 weeks and adverse events were graded. A total of 23 patients from six p...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,多中心研究

    doi:10.1097/CAD.0b013e328302eb15

    authors: Tokudome N,Ito Y,Hatake K,Toi M,Sano M,Iwata H,Sato Y,Saeki T,Aogi K,Takashima S

    更新日期:2008-08-01 00:00:00

  • D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTC Gynaecological Cancer Co-operative Group Study.

    abstract::Between March and September 1988, 74 patients with progressive ovarian cancer after prior platinum-based therapy were treated with the luteinizing hormone-releasing hormone (LHRH) agonist Triptorelin (Decapeptyl degrees). Treatment consisted of i.m. injection of 3.75 mg of microencapsulated Triptorelin on days 1, 8 an...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1097/00001813-200102000-00010

    authors: Duffaud F,van der Burg ME,Namer M,Vergote I,Willemse PHB,ten Bokkel Huinink W,Guastalla JP,Nooij,Kerbrat P,Piccart M,Tumolo S,Favalli G,van der Vange N,Lacave AJ,Wils J,Splinter TA,Einhorn N,Roozendaal KJ,Rosso R,Ve

    更新日期:2001-02-01 00:00:00

  • Inhibition of breast tumor growth in mice after treatment with ceramide analog 315.

    abstract::The aim of this study was to evaluate the anticancer and antitumor activities of ceramide analog 315 in nude mice. Nude mice (n=10) were injected bilaterally with 5×10 MDA-MB-231 cells on each side. Tumors were allowed to form for 2 weeks. The mice were then divided into two groups (n=5 in each group). The control gro...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000675

    authors: Ponnapakkam T,Saulsberry T,Hill T,Hill-Odom M,Goyal N,Anbalagan M,Liu J,Foroozesh M

    更新日期:2018-10-01 00:00:00

  • Enhanced anticancer effect of MAP30-S3 by cyclosproin A through endosomal escape.

    abstract::Cyclosporin A (CsA) is a calcium antagonist and can enhance the efficacy of some protein drugs, but its mechanism remains unknown. In this study, MAP30, a ribosome-inactivating protein reported to have apoptotic effects on cancer cells, was fused with S3, an epidermal growth factor receptor (EGFR)-targeting peptide. I...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000649

    authors: Song ZT,Zhang LW,Fan LQ,Kong JW,Mao JH,Zhao J,Wang FJ

    更新日期:2018-09-01 00:00:00

  • Novel mechanisms involving chemically modified tetracycline 3 cytotoxicity.

    abstract::Chemically modified tetracycline 3 (CMT-3) is a potential anticancer drug because of its retained matrix metalloproteinases inhibitory property. In the present study,we showed that CMT-3 significantly inhibited the growth and proliferation of human hepatocellular carcinoma HepG2 cells. Novel mechanisms including incre...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/cad.0000000000000144

    authors: Zhao L,Xu J,Jiao Y,Wang H,Fan S

    更新日期:2014-11-01 00:00:00

  • Galactosylated gelatin nanovectors of doxorubicin inhibit cell proliferation and induce apoptosis in hepatocarcinoma cells.

    abstract::We have synthesized and characterized doxorubicin (DOX)-loaded galactosylated gelatin nanovectors using in vitro and in vivo for targeting liver cells including hepatocarcinoma cells. Galactosylated and nongalactosylated gelatin nanovectors (GL-GN-DOX and GN-DOX) were spherical in shape and had mean sizes of about 95....

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e328351424f

    authors: Garg M,Madan J,Pandey RS,Sardana S,Katyal A,Chandra R

    更新日期:2012-09-01 00:00:00

  • Malignant phenotype of renal cell carcinoma cells is switched by ukrain administration in vitro.

    abstract::We investigated whether Ukrain modulates the malignant phenotype of clear cell renal cell carcinoma (ccRCC) cells Caki-1, Caki-2, and ACHN treated with four doses (5, 10, 20, and 40 μmol/l) for 24 and 48 h. The epithelial-to-mesenchymal transition markers E-cadherin, β-catenin, and vimentin were analyzed by immunofluo...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e328346c7f7

    authors: Gagliano N,Pettinari L,Aureli M,Martinelli C,Colombo E,Costa F,Carminati R,Volpari T,Colombo G,Milzani A,Dalle-Donne I,Gioia M

    更新日期:2011-09-01 00:00:00

  • The effect of imatinib mesylate (Glivec) on human tumor-derived cells.

    abstract::Imatinib mesylate is a specific inhibitor of the Bcr-Abl protein tyrosine kinase that competes with ATP for its specific binding site in the kinase domain. It has activity against platelet-derived growth factor receptor alpha and beta (PDGFR-alpha and -beta), and c-kit, the receptor for stem cell factor. We have used ...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/01.cad.0000215062.16308.41

    authors: Knight LA,Di Nicolantonio F,Whitehouse PA,Mercer SJ,Sharma S,Glaysher S,Hungerford JL,Hurren J,Lamont A,Cree IA

    更新日期:2006-07-01 00:00:00

  • Bevacizumab: a safe and effective treatment in a patient with advanced colorectal cancer and repeated removal of metastases.

    abstract::Bevacizumab has been shown to be effective combined with chemotherapy for first-line treatment of advanced colorectal cancer, but little information is available about its efficacy and safety in patients who may be candidates for surgery at any time during the disease. The case history of a female patient with colorec...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/01.cad.0000349778.09614.54

    authors: Castro-Carpeño Jd,Moyano MS,Sáenz EC,Belda-Iniesta C,Batlle JF,Barón MG

    更新日期:2009-04-01 00:00:00

  • Evidence of extended (>7 years) activity of bevacizumab and metronomic cyclophosphamide in a patient with platinum-resistant low-grade serous ovarian carcinoma.

    abstract::A patient with platinum resistant low-grade serous ovarian carcinoma had an objective response to therapy with bevacizumab and evidence of extended activity (>7 years). This case report adds to the growing literature regarding the use of bevacizumab in low-grade serous ovarian carcinoma. ...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e328363b64e

    authors: Rose PG,Roma A

    更新日期:2013-10-01 00:00:00

  • Successful treatment with personalized dosage of imatinib in elderly patients with gastrointestinal stromal tumors.

    abstract::Imatinib is the standard first-line therapy for metastatic gastrointestinal stromal tumors. It has markedly improved the prognosis and outcome of patients affected by gastrointestinal stromal tumors, especially in the case of exon 11 KIT mutations. Imatinib-associated adverse events are generally mild to moderate; how...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000331

    authors: Saponara M,Gatto L,Di Nunno V,Tabacchi E,Fanti S,Di Scioscio V,Nannini M,Gruppioni E,Altimari A,Fiorentino M,Santini D,Ceccarelli C,Zompatori M,Biasco G,Pantaleo MA

    更新日期:2016-04-01 00:00:00

  • 1,4-Anthraquinone: an anticancer drug that blocks nucleoside transport, inhibits macromolecule synthesis, induces DNA fragmentation, and decreases the growth and viability of L1210 leukemic cells in the same nanomolar range as daunorubicin in vitro.

    abstract::1,4-Anthraquinone (AQ) was synthesized and shown to prevent L1210 leukemic cells from synthesizing macromolecules and growing in vitro. In contrast, its dihydroxy-9,10anthraquinone precursor, quinizarin, was inactive. The antitumor activity of AQ was compared to that of daunorubicin (DAU), which is structurally differ...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-200006000-00004

    authors: Perchellet EM,Magill MJ,Huang X,Dalke DM,Hua DH,Perchellet JP

    更新日期:2000-06-01 00:00:00

  • Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity.

    abstract::Chemotherapy for breast cancer is given on the basis of empirical information from clinical trials, an approach which falls to take into account the known heterogeneity of chemosensitivity between patients. Previous attempts to determine chemosensitivity ex vivo have been disappointing, but in this study results from ...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章

    doi:10.1097/00001813-199608000-00002

    authors: Cree IA,Kurbacher CM,Untch M,Sutherland LA,Hunter EM,Subedi AM,James EA,Dewar JA,Preece PE,Andreotti PE,Bruckner HW

    更新日期:1996-08-01 00:00:00